High HIV-1 Drug Resistance in Togo
Author Information
Author(s): Dagnra Anoumou Y, Vidal Nicole, Mensah Akovi, Patassi Akouda, Aho Komi, Salou Mounerou, Monleau Marjorie, Prince-David Mireille, Singo Assétina, Pitche Palokinam, Delaporte Eric, Peeters Martine
Primary Institution: Centre National de Référence des tests VIH-IST/PNLS and Laboratoire BIOLIM, FMMP/UL, Lomé, Togo
Hypothesis
What is the prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo?
Conclusion
The study found a high prevalence of drug-resistant HIV strains among patients receiving first-line antiretroviral treatment in Togo.
Supporting Evidence
- 30.8% of patients experienced virologic failure.
- 24.5% of all patients had drug-resistance mutations.
- All patients with resistance were resistant to non-nucleoside reverse-transcriptase inhibitors.
Takeaway
Many people in Togo who are taking HIV medicine have viruses that don't respond to the treatment, which is a big problem.
Methodology
Patients on HAART for 10-14 months were enrolled, and viral load and drug-resistance testing were performed.
Potential Biases
Self-reported treatment history may lead to underreporting of prior ARV use.
Limitations
The study only included patients still receiving treatment, which may not represent the overall population.
Participant Demographics
Median age was 37 years, with 35.1% male participants.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website